BIEL's easiest, fastest and most likely path to success is

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
213
BIEL's easiest, fastest and most likely path to success is to generate a $400k revenue quarter and/or a $1.5 million revenue year (or if management hints Q1 2025 was profitable, or Q2 will be). A $400k revenue quarter would achieve cash flow positive/profitability and increase the pps to copper, which would solve most of BIEL's problems and open up a world of opportunities for the company.

BIEL COULD HIT COPPER IN THE "BLINK OF AN EYE"!
The first catalyst will likely be the announcement of a partner for the USA, which could come any day. The key statement from the annual report is "The Company has focused attention on seeking a distribution and licensing partner for the OTC US market". If investors value this partnership at $300k (and add it to the $496k of mostly international revenue reported for 2024), the pps gets out of the trips. If the investor valuation is $1 million, then the pps hits COPPER! The last time this happened (KT deal in 2021), BIEL soared 1,600%.

BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). The $40 million tax-loss carry forward will make the first $40 million in profits tax free and accelerate the path to profitability.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Sales Focus Inc. Awarded as Leading Medical Outsourcing Service

Updated Category News Views 112

Sales Focus Inc.: Leading the Way in Healthcare Outsourcing Sales Focus Inc. (SFI) proudly announces its recognition as the Top Healthcare and Medical Sales Outsourcing Service for 2025. This prestigious accolade showcases the company's vital role in revolutionizing the healthcare sector with its innovative full-lifecycle sales execution model and robust industry...

Continue Reading
The Rise of Autonomous Data Platforms in the Tech Industry

Updated Category News Views 76

Exploring the Autonomous Data Platform Market Growth The world of data management is rapidly evolving, with the Autonomous Data Platform Market projected to reach an impressive USD 14.96 billion by 2032. This explosive growth expands at a significant CAGR of 27.89% from its current valuation, representing a fundamental shift in how organizations interact with their data....

Continue Reading
Enpro's Recent Insider Activity Signals Strong Future Potential

Updated Category News Views 177

Insider Purchase by William Abbey at Enpro In the latest SEC filing, the market received noteworthy news about Enpro. William Abbey, who serves as a Director at Enpro (NYSE:NPO), demonstrated significant confidence in the company by purchasing 567 shares for a total of $139,997. What This Purchase Indicates This insider transaction suggests a strong belief in Enpro's...

Continue Reading
Massive Increase in BNB Fund for Cancer Patients Unveiled

Updated Category News Views 168

BNB Donation Achieves Remarkable Growth Recently, an incredible story surfaced about the untouched donation made in BNB (CRYPTO: BNB) for cancer patients. This donation, originally valued at $200,000, has soared to an astonishing $39 million thanks to the surging market value of cryptocurrencies, particularly BNB. Impact of Cryptocurrency Fluctuation on Charity Funds...

Continue Reading
Bio X Cell Refreshes Brand Identity to Enhance Global Research Impact

Updated Category News Views 171

Bio X Cell Unveils a Fresh Brand Identity Bio X Cell, recognized as the global leader in functional antibodies tailored for in vivo and emerging preclinical models, has introduced a modernized brand identity. This change is a testament to nearly three decades of excellence in the field, seamlessly merging scientific innovation with expanding global capabilities in...

Continue Reading